Kindeva appoints David Stevens as new CEO
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
Improvements were also seen in complete response rates, duration of response, and time to next treatment
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
India in the Changing Landscape of Life-Sciences Research & Development
The AI Nurse Companion, designed as a language-first learning platform, allows students to gain real-world German language proficiency through immersive practice
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
Subscribe To Our Newsletter & Stay Updated